Oscar Health (NYSE:OSCR) Sets New 1-Year High – What’s Next?

Oscar Health, Inc. (NYSE:OSCR) hit a new 52-week high on Tuesday . The company traded as high as $29.89 and last traded at $29.86, with a volume of 5109147 shares. The stock had previously closed at $28.54.

Analysts Set New Price Targets

OSCR has been the topic of several research analyst reports. Wall Street Zen raised shares of Oscar Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 14th. UBS Group boosted their price objective on shares of Oscar Health from $15.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, May 7th. Wells Fargo & Company set a $20.00 price objective on Oscar Health and gave the stock an “equal weight” rating in a report on Thursday, June 4th. Wolfe Research assumed coverage on Oscar Health in a research report on Tuesday, May 5th. They issued a “peer perform” rating on the stock. Finally, Robert W. Baird lifted their target price on Oscar Health from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Oscar Health currently has an average rating of “Hold” and a consensus target price of $20.78.

Oscar Health Price Performance

The company has a current ratio of 1.11, a quick ratio of 1.11 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.50 billion, a P/E ratio of -48.01, a PEG ratio of 2.09 and a beta of 2.37. The company has a fifty day simple moving average of $22.48 and a two-hundred day simple moving average of $17.19.

Oscar Health (NYSE:OSCR) last issued its earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.96. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.26%. The company had revenue of $4.65 billion for the quarter, compared to analyst estimates of $4.90 billion. During the same quarter last year, the firm earned $0.92 EPS. The company’s revenue for the quarter was up 52.6% on a year-over-year basis. Sell-side analysts expect that Oscar Health, Inc. will post 0.47 EPS for the current fiscal year.

Insider Transactions at Oscar Health

In other Oscar Health news, CEO Mark T. Bertolini acquired 1,000,000 shares of Oscar Health stock in a transaction on Monday, April 6th. The shares were purchased at an average cost of $11.92 per share, with a total value of $11,920,000.00. Following the completion of the purchase, the chief executive officer owned 10,196,876 shares in the company, valued at $121,546,761.92. The trade was a 10.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Janet Liang sold 12,475 shares of Oscar Health stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total transaction of $273,701.50. Following the sale, the insider directly owned 259,057 shares of the company’s stock, valued at $5,683,710.58. This represents a 4.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 189,660 shares of company stock valued at $4,283,140. 24.39% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Oscar Health

A number of institutional investors have recently made changes to their positions in OSCR. Vanguard Group Inc. increased its holdings in Oscar Health by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 20,701,250 shares of the company’s stock valued at $297,477,000 after purchasing an additional 540,851 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Oscar Health by 11.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,217,816 shares of the company’s stock worth $132,461,000 after buying an additional 910,320 shares during the last quarter. Morgan Stanley boosted its holdings in Oscar Health by 42.8% during the fourth quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock worth $97,918,000 after buying an additional 2,043,758 shares during the last quarter. Thrive Capital Management LLC grew its position in shares of Oscar Health by 33.4% during the 4th quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock worth $85,258,000 after buying an additional 1,588,395 shares during the period. Finally, BIT Capital GmbH grew its position in shares of Oscar Health by 545.0% during the 4th quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock worth $88,897,000 after buying an additional 5,227,152 shares during the period. 75.70% of the stock is owned by institutional investors and hedge funds.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.